Chemo- or Endocrine Adjuvant Therapy Alone or Combined in Postmenopausal Patients (GABG Trial 1)

  • W. Jonat
  • M. Kaufmann
  • U. Abel
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 115)


The natural history of operable breast cancer can be altered by adjuvant treatment (Lippmann 1986; Salmon 1987). Adjuvant combination chemotherapy (AC), e.g., cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) results in a significant prolongation of disease-free (DFS) and overall survival (OS) in premenopausal node-positive patients. Postmenopausal node-positive patients seem to benefit from endocrine therapy. These data were mainly obtained by overview analysis of randomized trials with treatment groups compared with groups receiving no adjuvant therapy (control) after mastectomy.


Breast Cancer Overall Survival Progesterone Receptor Primary Breast Cancer Endocrine Adjuvant Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bonadonna G, Brusamolino E, Valagussa P, et al. (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294: 405–410PubMedCrossRefGoogle Scholar
  2. Consensus Conference (1985) Adjuvant chemotherapy for breast cancer. JAMA 254: 3461–3463CrossRefGoogle Scholar
  3. EORTC: Breast Cancer Cooperative Group (1973) Standards for the assessment of estrogen receptors in human breast cancer. Eur J Cancer 9: 379–381Google Scholar
  4. Fisher ER, Sass R, Fisher B, et al. (1987) Pathologic findings from the National Surgical Adjuvant Breast Project: Correlations with concordant and discordant estrogen and progesterone receptors. Cancer 59: 1554–1559PubMedCrossRefGoogle Scholar
  5. Gelber RD, Goldhirsch A, for the Ludwig Breast Cancer Study Group (1986) A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol 4: 1772–1779PubMedGoogle Scholar
  6. Hubay C, Pearson OH, Marshall US (1980) Antiestrogen, cytotoxic chemotherapy and bacillus Calmette-Guérain vaccination in stage II breast cancer: a preliminary report. Surgery 87: 494–501PubMedGoogle Scholar
  7. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Statis Assoc 53: 457–481CrossRefGoogle Scholar
  8. Kaufmann M (1983) Biochemische prognostische Faktoren beim Mamma-Karzinom. In: Kubli F, Nagel GA, Kadach U, Kaufmann M (eds) Neue Wege in der Brustkrebsbehandlung Zuckschwerdt, München, pp 46–61Google Scholar
  9. (Aktuelle Onkologie, vol 8).
    Kaufmann M, Jonat W (GABG) (1984) Risk adapted adjuvant chemo-hormonotherapy in operable nodal positive breast cancer. In: Jones SE, Salmon SE (eds): Adjuvant therapy of cancer, vol 4. Grune and Stratton, New York, pp 369–378Google Scholar
  10. Kaufmann M, Jonat W, Caffíer H, Hilfrich J, Melchert F, Mahlke M, Abel U, Maass H, Kubli F for the Gynecological Adjuvant Breast Cancer Group (1985) Adjuvant chemo-hormonotherapy selected by axillary node and hormone receptor status in node-positive breast cancer. Reviews Endocrine-Related Cancer Supp 17: 57–63Google Scholar
  11. Lippmann ME (ed) (1986) NIH Consensus Development Conference on adjuvant chemotherapy and endocrine therapy for breast cancer 1985. NCI MonogrGoogle Scholar
  12. Ludwig Breast Cancer Study Group (1984) Randomized trial of chemo-endocrine therapy, endocrine therapy and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastases. Lancet I: 1256–1260Google Scholar
  13. Peto R, Pike MC, Armitage P et al. (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient: Analysis and examples. Br J Cancer 35: 1–39PubMedCrossRefGoogle Scholar
  14. Rose C, Thorpe S, Anderson KW et al (1985) Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high estrogen receptor value. Lancet I: 16–19CrossRefGoogle Scholar
  15. Salmon SE, Jones SE (1979) Studies of the combination of adriamycin and cyclophosphamide (alone or with other agents) for the treatment of breast cancer. Oncology 36: 40–44PubMedCrossRefGoogle Scholar
  16. Salmon SE (ed) (1987) Adjuvant therapy of cancer, vol 5. Grune and Stratton, New YorkGoogle Scholar
  17. Scottish Cancer Trial (1987) Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial. Lancet II: 171–175Google Scholar
  18. Wilson RE, Donegan WL, Mettlin C (1984) The 1982 national survey of carcinoma of the breast in the United States. American College of Surgeons. Surg Gynecol Obstet 159: 309–318PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1989

Authors and Affiliations

  • W. Jonat
    • 1
  • M. Kaufmann
    • 1
  • U. Abel
    • 1
  1. 1.Abteilung für Gynäkologie und GeburtshilfeUniversitätsklinik HamburgHamburg 20Germany

Personalised recommendations